Korean J Pediatr Hematol Oncol.
2004 Oct;11(2):265-270.
A Case of Ganciclovir-resistant CMV Antigenemia by UL97 Phosphotransferase Mutant Strain after Cord Blood Transplantation
- Affiliations
-
- 1Department of Pediatrics, The Catholic University of Korea, College of Medicine, Seoul, Korea. cngped@catholic.ac.kr
- 2Department of Internal Medicine, The Catholic University of Korea, College of Medicine, Seoul, Korea.
Abstract
- Despite the availability of effective antiviral drugs, human cytomegalovirus (CMV) infection is still a serious life-threatening complication in recipients of allogeneic hematopoietic stem cell transplantation. Ganciclovir (GCV) preemptive therapy is currently the usual treatment for CMV disease and antigenemia. However, prolonged GCV therapy results in the emergence of drug-resistant virus. Most GCV-resistant clinical CMV isolates contain a mutation in the UL97 phosphotransferase gene. We report a case that GCV-resistant CMV antigenemia by UL97 phosphotransferase mutant strain at codon 460 and 605 which was improved by reduction of immunosuppressants for posttransplant lymphoproliferative disease after unrelated cord blood transplantation.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The First Case of Ganciclovir-Resistant Cytomegalovirus Colitis with a 597-600 Deletion in UL97 Gene after Stem Cell Transplantation in Korea
- Antiviral Resistance in Human Cytomegalovirus Due to UL54 Mutations Without UL97 Mutations
- The Effect of Preemptive Therapy with Intravenous Ganciclovir Followed by Oral Ganciclovir against Cytomegalovirus Infection after Allogeneic Peripheral Blood Stem Cell Transplantation
- Disseminated Cytomegalovirus Infection after Renal Transplantation: A Case Report
- CMV Disease
